Sunitinib Malate clinical trials

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

This study is for people with advanced kidney cancer (non-clear cell type) that hasn't spread too widely. It compares a new combination of drugs (XL092 + nivolumab) with a standard treatment (sunitinib) to see which works better. Participants haven't had prior cancer medicine for their advanced kidney cancer.